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Angiogenesis plays an essential role in the development of a neoplastic 
tumour by conditioning both its growth and the formation of metastases. The in-
duction of blood vessel growth occurs under the influence of proangiogenic fac-
tors, among which Vascular Endothelial Growth Factor (VEGF) seems to be the 
most important. The aim of this research was to study the level of VEGF meas-
ured by ELISA in the serum of dogs with neoplasms of the oral cavity. The study 
material comprised samples of neoplastic tissue from 17 operated dogs and the se-
rum of the examined animals as well as of dogs from the control group. The tissue 
samples were taken from dogs of different breeds, aged 6–14 years. The tumour 
type was determined in accordance with the applicable WHO classification. 
Blood samples taken from sick dogs and from animals of the control group were 
centrifuged, and immunoenzymatic labelling of VEGF was performed in the ob-
tained serum using ELISA and R&D system reagents (Quantikine Canine VEGF). 
All stages of VEGF labelling were performed according to the recommendation 
of the test manufacturer. The median of VEGF in the serum of the dogs with neo-
plasms of the oral cavity was 40.64 pg/mL. The lowest value of 14.26 pg/mL was 
observed in the case of fibrosarcoma, and the highest value of 99.19 pg/mL in the 
case of squamous cell carcinoma. The VEGF median in the control group 
amounted to 11.14 pg/mL whereas the VEGF value in the groups of animals di-
agnosed with benign tumours ranged between 2.30 and 19.74 pg/mL. Elevated 
VEGF in the blood serum, in comparison with the benign tumour group and the 
control group, was observed in all examined neoplasms of the oral cavity. It was 
suggested that overexpression of VEGF can have a prognostic value and is useful 
in the early detection of neoplasms.  
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Cancerous hyperplasia depends to a large extent on neoangiogenesis, i.e. 
the process of creating a network of blood vessels in tumours. Numerous publi-
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cations have dealt with angiogenesis and its role in many cancers of humans and 
animals. The increased density of blood vessels in comparison to normal tissues 
has been noted in cancers of the large intestine, uterus, breast, lungs, oral cavity 
as well as in cancers of the brain in humans. The number of newly created ves-
sels has an influence on the progression and course of the disease. Moreover, the 
proper supply of blood to the tumour is conducive to its cells getting into the 
blood circulation and initiating the process of metastases (Bałan and Słotwiński, 
2008; Michailidon et al., 2008). 
The development of molecular biology and genetic engineering has con-
tributed to our better knowledge and understanding of the phenomena related to 
vessel formation in tumours and the development of cancer. It has been shown 
that the induction of vessel growth is a process subject to a strict control by posi-
tive and negative regulators of angiogenesis (Bałan and Słotwiński, 2008; Szala, 
2009). When this balance is upset, angiogenesis occurs. A lot of proteins have 
been described as proangiogenic factors, however, Vascular Endothelial Growth 
Factor (VEGF) poses to be potentially the most important factor involved in the 
process of tumour development (Dvorak et al., 1988; Ferrara, 1999; Bałan and 
Słotwiński, 2008). It is a glycosylated homodimer whose molecular weight is 
46–48 kDa. Through alternative mRNA maturation, 7 VEGF isoforms are formed 
[VEGF121, VEGF145, VEGF148, VEGF165, VEGF183, VEGF189, VEGF206] (Ferrara, 
1999; Polverini, 2002; Roselli et al., 2003; Bałan and Słotwiński, 2008; Szala, 
2009). The isoforms differ in the number of amino acids as well as in biochemi-
cal and biological properties. VEGF121 and VEGF165 are the most often examined 
isoforms. Depending on whether VEGF is anchored in the extracellular matrix 
(ECM), or if it is in a non-bound form, reactions of endothelial cells to the 
growth factor are different. Anchored VEGF (mainly VEGF165) is better recog-
nised by receptors located on the processes of endothelial cells. VEGF121 is far 
less recognised. It is therefore believed that the vessel networks formed with the 
contribution of VEGF165 are denser than those formed with the contribution of 
VEGF121 (Iruela-Arispe, 2008; Szala, 2009). 
VEGF binds to three receptors that are located in endothelial cells and 
contain a tyrosine kinase domain: VEGFR-1 (Flt-1-fms-like tyrosine kinase-1), 
VEGFR-2 (KDR-kinase domain region) and VEGFR-3 (Dvorak, 2002; Takahashi 
and Shibuya, 2005). The presence of VEGF receptors was also observed in 
healthy lung, skin and bladder tissue in dogs (Uchida et al., 2008). 
VEGF is secreted by many cells: T lymphocytes, macrophages, mono-
cytes, fibroblasts, platelets after activation, and especially by neoplastic cells. It 
has been shown that angiogenesis is one of the ways by which neoplastic cells 
compensate for the lack of oxygen, and VEGF plays an important role at this 
stage (Dvorak et al., 1988; Szala, 2009). The most important factor participating 
in its expression is hypoxia, during which the hypoxia inducible factor HIF-1 is 
increased in the cells. A stimulation of VEGF expression can also occur under 
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the influence of cytokines, interleukins and in consequence of mutation of some 
oncogenes, e.g. the p53 gene. VEGF is also the basis for the so-called angiogenic 
phenotype, i.e. the ability to produce and secrete proangiogenic factors by neo-
plastic cells (Szala, 2009). 
VEGF results in mitogenesis of the vascular endothelial cells, causing 
their increased proliferation, migration and formation of vessels in a neoplastic 
tumour (Wergin and Kaser-Hotz, 2004; Sacewicz et al., 2009). Furthermore, this 
factor stimulates vascular permeability and shows autocrine activity, i.e. the pro-
tection of neoplastic cells against stress caused by chemotherapy and radiother-
apy – the factor increases the survivability of neoplastic cells (Volk et al., 2008). 
Moreover, VEGF blocks the maturation and differentiation of dendritic cells, 
thus significantly weakening the immunological response (Wąsik-Szczepanek 
and Koczkodaj, 2008). 
Elevated serum VEGF levels have also been observed in human tumours. 
Studies have also been conducted into VEGF levels in the serum of animals di-
agnosed with e.g. skin and subcutaneous tissue cancer as well as mammary gland 
cancer. It has been demonstrated that, in such cases, VEGF overexpression can 
indicate a malignant course of the disease and a higher potential for metastasis 
(Kato et al., 2007; Sobczyńska-Rak, 2012). 
The increased level of VEGF often correlates with angiogenesis. The over-
expression of VEGF has also been confirmed in dogs diagnosed with oral mela-
nomas as well as skin and subcutaneous tissue cancer. It has been demonstrated 
that VEGF level was significantly higher in melanomas than in benign tumours 
or in the serum of healthy dogs (Rawlings et al., 2003; Taylor et al., 2007; 
Sobczyńska-Rak et al., 2009; Smedley et al., 2011). 
The aim of this research was to study the level of VEGF measured by 
ELISA in the serum of dogs with neoplasms of the oral cavity. 
 
 
Materials and methods 
The materials used in the study comprised samples of neoplastic tissue 
from 17 operated dogs and the serum of the examined animals as well as of dogs 
from the control group. 
The animals were subjected to surgery at the Department and Clinic of 
Animal Surgery of the University of Life Sciences in Lublin after being diag-
nosed with neoplastic tumours occurring in their gums. Tissue samples were taken 
from the aforementioned 17 dogs of different breeds, aged 6–14 years (Table 1). 
In the affected dogs, thoracic radiographic examinations were carried out 
to confirm or exclude metastasis. The level of VEGF in the serum of affected 
animals and in dogs of the control group was determined. 
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Table 1. Results of histopathological diagnosis and immunoenzymatic examination in the test group 
No. Description Location of tumours Histopathological diagnosis VEGF level, pg/mL 
Group A 
 1 Mixed breed, ♂, 10 years old Incisive and canine teeth, right mandible Squamous cell carcinoma 28.03 
 2 German Shepherd, ♂, 11 y. o.  Molar teeth, right mandible  Squamous cell carcinoma 99.19 
 3 Collie rough, ♂, 14 y. o. Molar teeth, left mandible, metastases in lung Squamous cell carcinoma 65.21 
 4 Mixed breed, ♂, 10 y. o. Premolar teeth, left mandible  Amelanotic melanoma 34.66 
 5 Cocker spaniel, ♂, 9 y. o. Molar teeth, left maxilla Amelanotic melanoma 52.55 
 6 Dachshund, ♂, 11 y. o. Molar teeth, right maxilla, metastases in nasal sinus Amelanotic melanoma 64.10 
 7 Collie rough, ♂, 6 y. o. Molar teeth, left mandible Amelanotic melanoma 15.71 
 8 Bullmastiff, ♂, 8 y. o. Premolar teeth, right mandible  Fibrosarcoma 14.26 
 9 Mixed breed, ♀, 10 y. o. Molar teeth, right maxilla Fibrosarcoma 17.41 
10 Mixed breed, ♂, 8 y. o. Premolar and molar teeth, right mandible, metastases in lung Fibrosarcoma 46.62 
Group B 
 1 Mixed breed, ♂, 7 y. o. Molar teeth, left mandible Epulides  19.29 
 2 Mixed breed, ♂, 8 y. o. Molar teeth, left maxilla Epulides 2.30 
 3 Boxer, ♀, 10 y. o. Premolar teeth, left mandible Epulides 8.61 
 4 Mixed breed, ♂, 9 y. o. Premolar teeth, left mandible Epulides 9.26 
 5 Cocker spaniel, ♂, 9 y. o. Molar teeth, right maxilla Fibroma 19.74 
 6 Dachshund, ♂, 11 y. o. Incisive teeth, left mandible Fibroma 5.77 
 7 Mixed breed, ♂, 12 y. o. Incisive teeth, left maxilla Papilloma  8.09 
Control group 
 1 Mixed breed, ♂, 7 y. o. Healthy  11.26 
 2 Boxer, ♀, 5 y. o. Healthy  0.1 
 3 Mixed breed, ♂, 4 y. o. Healthy  13.04 
 4 Mixed breed, ♂, 4 y. o. Healthy  13.03 
 5 Mixed breed, ♂, 2 y. o. Healthy  5.63 
 6 German Shepherd, ♂, 6 y. o. Healthy  11.68 
 7 Labrador, ♂, 4 y. o. Healthy  10.62 
 8 Mixed breed, ♂, 7 y. o. Healthy  12.53 
 9 Mixed breed, ♂, 6 y. o. Healthy  7.2 
10 Mixed breed, ♂, 2 y. o. Healthy  11.02 
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The control group comprised 10 healthy dogs (mixed breed, Labrador, 
German Shepherd and Boxer, 9 males and 1 female), aged 2–7 years, which were 
brought in for neutering. 
After surgical extraction of the tumour, the obtained material was deliv-
ered to the Department of Pathological Anatomy of the Faculty of Veterinary 
Medicine at the University of Life Sciences in Lublin. Specimens of tumours 
were preserved in 10% buffered formalin for 24 h. The diagnosis was established 
by the examination of samples stained with haematoxylin and eosin, and the type 
of tumour was determined according to the applicable WHO classification. 
Blood taken from the dogs and from animals of the control group was cen-
trifuged and the obtained serum was frozen at –75 °C. The level of VEGF in the 
blood serum was determined by ELISA test (Quantikine Canine Immunoassay, 
R&D Systems). Every step of the VEGF determination assay was performed in 
accordance with the manufacturer’s guidelines. 
A statistical analysis was carried out to verify any significant correlations 
between the level of VEGF in the serum of affected animals and in animals of 
the control group. The Mann-Whitney test was employed to verify the signifi-
cance of the observed discrepancies between results of the two groups when the 
variables were not normally distributed. 
 
 
Results 
Histopathological examinations confirmed the malignant character of 10 
tumours, whereas in 7 cases the tumours were found to be benign. Therefore, the 
study group of animals was divided into two subgroups: Group A included ani-
mals diagnosed with malignant tumours: 3 cases of squamous cell carcinoma, 3 
cases of fibrosarcoma, and 4 cases of amelanotic melanoma. The second sub-
group (Group B) included animals diagnosed with benign tumours, i.e. epulides, 
fibromas and papillomas. The detailed results are presented in Table 1. 
The median concentration of VEGF in the serum of dogs diagnosed with 
malignant tumours of the oral cavity (Group A) was 40.64 pg/mL [14.26–
99.19 pg/mL]. The lowest value of 14.26 pg/mL was observed in the blood se-
rum of animals suffering from fibrosarcomas, while the highest (99.19 pg/mL) in 
that of dogs diagnosed with squamous cell carcinoma (Table 1). In the case of 
melanomas, the serum levels of VEGF ranged between 15.71 and 64.10 pg/mL. 
In the case of benign tumours, the observed blood serum levels of VEGF were 
lower and ranged between 2.30 and 19.74 pg/mL (the detailed results are pre-
sented in Table 1). In the control group, the recorded VEGF levels were between 
0.1 and 13 pg/mL. The median was 11.14 pg/mL (Table 2). 
A statistically significant elevation of serum VEGF levels was observed in 
animals suffering from malignant tumours (Group A), compared with the control 
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group (P < 0.001) and with dogs diagnosed with benign tumours (Group B; P < 
0.01). The results obtained for dogs of Group B did not significantly differ from 
those of the control group (P > 0.05). The detailed results are presented in Table 2. 
Table 2 
Comparison of VEGF characteristics with those of the control group 
Group Median VEGF (pg/mL) 
Min. VEGF 
(pg/mL) 
Max. VEGF 
(pg/mL) 
SD 
VEGF n 
Group A 40.64 14.26 99.19 27.31 10 
Control group 11.14 0.1 13.04 4.13 10 
Z = 3.78 (***) P < 0.001 
Group B 8.61 2.30 19.74 6.62 7 
Control group 11.14 0.1 13.04 4.13 10 
Z = 0.29 (–) P > 0.05 
Group A 40.64 14.26 99.19 27.31 10 
Group B 8.61 2.30 19.74 6.62 7 
Z = 2.83 (**) P < 0.01 
 
 
Discussion 
The risk factors influencing the development of neoplastic lesions of the 
oral cavity include increased exposure to harmful environmental factors and 
chronic inflammatory state of the periodontium. Lesions are located mainly on 
the gums, soft palate, tongue and buccal mucosa (Sobczyńska-Rak et al., 2009). 
In histopathological preparations taken from the neoplasms, three types of 
malignant neoplasms were recognised: malignant melanoma, squamous cell car-
cinoma and fibrosarcoma. According to data of the literature, these are the most 
often diagnosed malignant tumours of the oral cavity in dogs (Bergman, 2007; 
Sapierzyński et al., 2007; Sobczyńska-Rak et al., 2009). These tumours often in-
filtrate the oral mucosa and muscles of the splanchnocranium. In advanced 
stages, metastases to cranial bones, local lymph nodes and lungs are present. 
The formation of blood vessels in a tumour is considered to be a condition 
of neoplastic progression (Bałan and Słotwiński, 2008; Szala, 2009). 
Comparative studies have been conducted to analyse the chemical struc-
ture of VEGF in humans and animals. It has been demonstrated that the amino 
acid sequences in the areas responsible for receptor binding are identical in hu-
mans and animals (Scheidegger et al., 1999; Mohammed et al., 2002). 
Attempts have been made to determine VEGF in the blood serum in dogs 
with spontaneously occurring tumours with the use of a human ELISA test which 
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indicated 80–90% of tumours manifested morphologically. The mean VEGF 
level observed with various types of malignant tumours was between 7.2 pg/mL 
and 12.6 pg/mL in oral melanoma, whereas in the case of benign tumours the 
value was significantly lower (0.9–1.3 pg/mL) (Wergin and Kaser-Hotz, 2004; 
Wergin et al., 2006). Meanwhile, Troy et al. (2006), when studying VEGF in 
dogs suffering from malignant tumours, obtained results between 2.5 pg/mL and 
as high as 274 pg/mL. Also, Kato et al. (2007) tested VEGF using a Human 
VEGF Quantikine ELISA Kit. They confirmed elevation of VEGF levels in the 
blood serum of dogs diagnosed with malignant mammary gland tumours, with 
the recorded values ranging from not detectable to 992.9 pg/mL. 
In our own research performed with the use of the Canine VEGF Quanti-
kine ELISA Kit, which has been available for several years now, different results 
were obtained. The mean VEGF concentration in the blood serum of dogs diag-
nosed with malignant tumours ranged between 14.26 and 65.21 pg/mL, whereas 
in dogs with benign tumours the values were between 2.30 and 19.74 pg/mL. 
Evidently, despite the significant homology of human and canine VEGF, consid-
erable discrepancies can be observed between the respective results, which 
strongly suggests that in order to standardise the results of scientific studies, spe-
cies-specific assays should always be used. 
The increased expression of VEGF, as mRNA in neoplastic tissue as well 
as the protein itself in plasma, serum or urine, has been observed in many types 
of neoplastic disease in humans, including cancer of the colon, stomach, breast, 
lung, prostate, kidney, and urinary bladder (Sobczyńska-Rak, 2012). The in-
creased level of VEGF often correlates with angiogenesis and the presence of 
metastases. In some neoplasms, e.g. leukaemia, the level of growth factor corre-
lates with a shorter survival time and a lower probability of full remission (Łojko 
and Komarnicki, 2004; Wąsik-Szczepanek and Koczkodaj, 2008). 
It has been shown that angiogenesis plays an essential role in the devel-
opment of melanomas in humans. Higher levels of VEGF in the serum occur in 
patients with an advanced neoplastic process and are indicative of a negative 
prognosis and shorter periods of remission and, according to several authors’ 
contention, they can have a certain prognostic value (Ugurel et al., 2001; Ascierto 
et al., 2004; Mackiewicz and Kwinta, 2010). 
It has been shown that the growth factor is present not only in neoplastic 
cells but also in stromal cells of a tumour and is, to a large extent, responsible for 
the uncontrolled growth and the formation of metastases (Smith et al., 2000; Măr-
găritescu et al., 2009). As a result of the research, evaluation of the expression of 
VEGF and its receptors was demonstrated to be a reliable prognostic factor in 
squamous cell carcinoma of the oral cavity and tongue in humans, as well as in 
those of the oral cavity and nasal epithelium in dogs. Owing to this, the develop-
ment and local recurrence as well as the formation of distant metastases can be 
monitored (Smith et al., 2000; López de Cicco et al., 2004; Shiomitsu et al., 2009). 
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Understanding the distribution and role of VEGF in the progression of 
squamous cell carcinoma of the oral cavity is a key to planning new therapeutic 
strategies (Mărgăritescu et al., 2009). 
From the clinician’s perspective the crucial observation was whether the 
excised lesions were of benign or malignant character. This determination was 
performed on the basis of haematoxylin and eosin (HE) staining and the tumour 
type was categorised in accordance with the WHO classification (Head et al., 
2003). The study may have been supplemented by additional determination of 
the proliferation ability (grade, Ki67, mitotic activity), but such tests were not 
performed under the described research regime as the objective of the study was 
to determine the blood serum VEGF levels in animals diagnosed with malignant 
tumours and to relate them to those observed in animals diagnosed with benign 
tumours and in healthy animals. 
In our own research, increased VEGF expression in comparison with the 
control group was observed in all malignant neoplasms of the oral cavity. The re-
sults were statistically significant. On analysing the results, it can be hypothe-
sised that VEGF plays a significant role in the angiogenesis of oral cavity tu-
mours in dogs. It can be assumed that the level of VEGF in the blood serum of 
affected animals can prove to be a viable indicator in assessing the malignancy of 
tumours and the prognosis. 
Investigating VEGF levels in particular types of malignant tumours and 
tumours of different characteristics will require further studies to be performed on 
a larger group of animals suffering from a specific type of cancer, e.g. squamous 
carcinoma with varying levels of histopathological malignancy. In such a re-
search the proliferation ability (grade, Ki67, mitotic activity) would likely play a 
more vital role in determining the correlation between serum VEGF level and 
different characteristics of the given type of tumour. Moreover, changes in VEGF 
concentrations in a given type of tumour may in the future constitute one of the 
main prognostic factors which will allow us to determine the animal’s predicted 
life expectancy, but this will require a further, extensive study. 
When analysed against the clinical picture of a neoplastic process, VEGF 
overexpression can influence the choice of the methods of surgical treatment and 
indicate the likelihood of its effectiveness. Antiangiogenic therapies with the use 
of monoclonal antibodies against VEGF or substances blocking its receptors 
seem to be promising, and clinical research in this direction is currently carried 
out on a large scale globally (Dvorak, 2002; Volk et al., 2008; Szala, 2009; 
Mackiewicz and Kwinta, 2010). 
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